In Cell Art and Merial agree research collaboration
Will evaluate In Cell Art nanocarrier technologies within Merial vaccines programme
In Cell Art, a French biotechnology company involved in macromolecular drug (siRNA or DNA) delivery systems, has agreed a research collaboration with animal health company Merial to evaluate In Cell Art’s nanocarrier technologies in the context of Merial's vaccines programme.
The aim of the collaboration is to create new opportunities to improve the efficacy of Merial's novel vaccine development targets.
‘This agreement highlights In Cell Art’s breakthrough nanocarrier technology for new vaccine development,’ said Chloé Bellocq, ceo, and Bruno Pitard, co-founder and scientific advisor of In Cell Art.
In Cell Art says the ICA614 nanocarrier, a DNA synthetic formulation, offers dramatic enhancement of the immunogenicity of plasmid DNA-encoding tumours or pathogen-derived antigens, a reduction in the dose of plasmid DNA, as well as an excellent safety profile.
ICA614 is currently being either used or tested by major vaccine companies. In Cell Art has also demonstrated that the ICA614 nanocarrier can increase the immunogenicity of sub-unit vaccines containing recombinant proteins.
